UA111844C2 - Фармацевтично прийнятні співкристали n-[2-(7-метокси-1-нафтил)етил]ацетаміду і способи їх одержання - Google Patents
Фармацевтично прийнятні співкристали n-[2-(7-метокси-1-нафтил)етил]ацетаміду і способи їх одержання Download PDFInfo
- Publication number
- UA111844C2 UA111844C2 UAA201313793A UAA201313793A UA111844C2 UA 111844 C2 UA111844 C2 UA 111844C2 UA A201313793 A UAA201313793 A UA A201313793A UA A201313793 A UAA201313793 A UA A201313793A UA 111844 C2 UA111844 C2 UA 111844C2
- Authority
- UA
- Ukraine
- Prior art keywords
- crystal
- naphthyl
- methoxy
- crystals
- still
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 119
- 238000000034 method Methods 0.000 title claims abstract description 23
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 title claims description 30
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 title 1
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960002629 agomelatine Drugs 0.000 claims abstract description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 86
- 239000000843 powder Substances 0.000 claims description 19
- 238000002844 melting Methods 0.000 claims description 16
- 230000008018 melting Effects 0.000 claims description 16
- 239000002904 solvent Substances 0.000 claims description 16
- 238000002441 X-ray diffraction Methods 0.000 claims description 15
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 11
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- 238000001069 Raman spectroscopy Methods 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 claims 1
- 241001279686 Allium moly Species 0.000 claims 1
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 claims 1
- 241000543381 Cliftonia monophylla Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000388430 Tara Species 0.000 claims 1
- 235000015241 bacon Nutrition 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000011888 snacks Nutrition 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 abstract description 30
- 238000002360 preparation method Methods 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 229960004106 citric acid Drugs 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000008186 active pharmaceutical agent Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 9
- 238000001237 Raman spectrum Methods 0.000 description 9
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 9
- 239000011976 maleic acid Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 9
- 239000012453 solvate Substances 0.000 description 8
- 238000000113 differential scanning calorimetry Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000012071 phase Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000012296 anti-solvent Substances 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000009878 intermolecular interaction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000001757 thermogravimetry curve Methods 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 102000001419 Melatonin receptor Human genes 0.000 description 2
- 108050009605 Melatonin receptor Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- -1 ether alcohols Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- QSIOUIPVORSGSV-UHFFFAOYSA-N 4-(7-methoxynaphthalen-1-yl)butanamide Chemical compound C1=CC=C(CCCC(N)=O)C2=CC(OC)=CC=C21 QSIOUIPVORSGSV-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 229910003986 SicO Inorganic materials 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000011093 chipboard Substances 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002484 serotonin 2C antagonist Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002460 vibrational spectroscopy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11075073.4A EP2517700B1 (en) | 2011-04-28 | 2011-04-28 | Pharmaceutically acceptable cocrystals of N-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation |
| PCT/EP2012/001761 WO2012146371A1 (en) | 2011-04-28 | 2012-04-25 | Pharmaceutically acceptable cocrystals of n-[2-(7-methoxy-1-naphtyl)ethyl]acetamide and methods of their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA111844C2 true UA111844C2 (uk) | 2016-06-24 |
Family
ID=44519907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201313793A UA111844C2 (uk) | 2011-04-28 | 2012-04-25 | Фармацевтично прийнятні співкристали n-[2-(7-метокси-1-нафтил)етил]ацетаміду і способи їх одержання |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8927771B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2517700B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5770928B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140008370A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103501777B (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013023471A2 (cg-RX-API-DMAC7.html) |
| EA (1) | EA024422B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2429348T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL228916A (cg-RX-API-DMAC7.html) |
| MX (1) | MX342807B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2517700T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2517700E (cg-RX-API-DMAC7.html) |
| RS (1) | RS52982B (cg-RX-API-DMAC7.html) |
| UA (1) | UA111844C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012146371A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201307688B (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012000132B1 (en) | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
| EP2551257A1 (en) * | 2011-07-28 | 2013-01-30 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of agomelatine with co-crystal-formers |
| US9409857B2 (en) | 2012-05-14 | 2016-08-09 | Shanghai Righthand Pharmtech, Co., Ltd. | Agomelatine sulfuric acid complex, and preparation method and application thereof |
| US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
| EP2743255B1 (en) | 2012-12-17 | 2016-06-22 | Dr. Reddy's Laboratories Ltd. | Cocrystal of agomelatine with phosphoric acid |
| ES2645223T3 (es) | 2013-06-06 | 2017-12-04 | Zentiva, K.S. | Formulaciones de agomelatina que comprenden agomelatina en forma de co-cristales |
| EP2810647A1 (en) * | 2013-06-06 | 2014-12-10 | Zentiva, a.s. | Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid |
| PL3027588T3 (pl) * | 2013-07-29 | 2020-11-02 | Les Laboratoires Servier | Kompleksy agomelatyny i kwasów sulfonowych, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające |
| FR3012142B1 (fr) * | 2013-10-17 | 2016-07-15 | Servier Lab | Nouveaux complexes d'agomelatine et d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2015013865A1 (en) * | 2013-07-29 | 2015-02-05 | Les Laboratoires Servier | Agomelatine sulfonic acids complexes and preparation thereof |
| CN105473551B (zh) * | 2013-07-31 | 2019-01-11 | 法国施维雅药厂 | 阿戈美拉汀和对甲苯磺酸的共晶的新形式、其制备方法和包含其的药物组合物 |
| WO2015013903A1 (en) * | 2013-07-31 | 2015-02-05 | Les Laboratoires Servier | NEW AGOMELATINE p-TOLUENESULFONIC ACID CO-CRYSTAL FORMS AND PREPARATION THEREOF |
| EA031053B1 (ru) * | 2013-07-31 | 2018-11-30 | Ле Лаборатуар Сервье | Новые формы сокристаллов агомелатина и п-толуолсульфоновой кислоты, способ их получения и фармацевтические композиции, которые их содержат |
| KR101404836B1 (ko) | 2014-03-21 | 2014-06-09 | 순천향대학교 산학협력단 | 아고멜라틴의 공결정 및 그의 제조방법 |
| KR101470794B1 (ko) | 2014-06-30 | 2014-12-08 | 순천향대학교 산학협력단 | 아고멜라틴 공결정의 제조 방법 및 이를 포함하는 조성물 |
| PL3075724T3 (pl) | 2015-03-31 | 2023-12-27 | F.I.S.- Fabbrica Italiana Sintetici S.P.A. | Stała postać agomelatyny |
| WO2017115284A1 (en) * | 2015-12-28 | 2017-07-06 | Leiutis Pharmaceuticals Pvt, Ltd. | Novel co-crystal forms of agomelatine |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524596A (ja) * | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
| WO2008035177A2 (en) * | 2006-09-18 | 2008-03-27 | Copharm | Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor |
| CN101481321B (zh) * | 2009-02-27 | 2012-04-18 | 上海医药工业研究院 | 阿戈美拉汀卤化氢复合物及其制备方法 |
| CN102106806B (zh) * | 2009-12-29 | 2013-04-17 | 上海中西制药有限公司 | 一种固体制剂的制备方法及所得固体制剂 |
| WO2012046253A2 (en) | 2010-10-08 | 2012-04-12 | Msn Laboratories Limited | Process for the preparation of n-[2- (7-methoxy-l-naphthyl) ethyl] acetamide and its novel crystalline forms |
| PH12012000132B1 (en) * | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
-
2011
- 2011-04-28 PT PT110750734T patent/PT2517700E/pt unknown
- 2011-04-28 EP EP11075073.4A patent/EP2517700B1/en not_active Not-in-force
- 2011-04-28 RS RS20130436A patent/RS52982B/sr unknown
- 2011-04-28 ES ES11075073T patent/ES2429348T3/es active Active
- 2011-04-28 PL PL11075073T patent/PL2517700T3/pl unknown
-
2012
- 2012-04-25 BR BR112013023471A patent/BR112013023471A2/pt not_active Application Discontinuation
- 2012-04-25 US US14/114,211 patent/US8927771B2/en not_active Expired - Fee Related
- 2012-04-25 EA EA201391574A patent/EA024422B1/ru not_active IP Right Cessation
- 2012-04-25 CN CN201280020790.9A patent/CN103501777B/zh not_active Expired - Fee Related
- 2012-04-25 UA UAA201313793A patent/UA111844C2/uk unknown
- 2012-04-25 MX MX2013012103A patent/MX342807B/es active IP Right Grant
- 2012-04-25 JP JP2014506792A patent/JP5770928B2/ja not_active Expired - Fee Related
- 2012-04-25 KR KR1020137024023A patent/KR20140008370A/ko not_active Ceased
- 2012-04-25 WO PCT/EP2012/001761 patent/WO2012146371A1/en not_active Ceased
-
2013
- 2013-10-16 IL IL228916A patent/IL228916A/en active IP Right Grant
- 2013-10-16 ZA ZA2013/07688A patent/ZA201307688B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012146371A1 (en) | 2012-11-01 |
| US8927771B2 (en) | 2015-01-06 |
| MX2013012103A (es) | 2014-01-24 |
| IL228916A0 (en) | 2013-12-31 |
| ES2429348T3 (es) | 2013-11-14 |
| IL228916A (en) | 2016-05-31 |
| JP2014522388A (ja) | 2014-09-04 |
| MX342807B (es) | 2016-10-13 |
| PL2517700T3 (pl) | 2013-12-31 |
| CN103501777A (zh) | 2014-01-08 |
| EP2517700A1 (en) | 2012-10-31 |
| EA024422B1 (ru) | 2016-09-30 |
| CN103501777B (zh) | 2015-08-19 |
| RS52982B (sr) | 2014-02-28 |
| BR112013023471A2 (pt) | 2016-12-13 |
| KR20140008370A (ko) | 2014-01-21 |
| EP2517700B1 (en) | 2013-07-17 |
| PT2517700E (pt) | 2013-10-14 |
| ZA201307688B (en) | 2015-04-29 |
| US20140051887A1 (en) | 2014-02-20 |
| JP5770928B2 (ja) | 2015-08-26 |
| EA201391574A1 (ru) | 2014-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA111844C2 (uk) | Фармацевтично прийнятні співкристали n-[2-(7-метокси-1-нафтил)етил]ацетаміду і способи їх одержання | |
| KR102881316B1 (ko) | 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태 | |
| US10377758B2 (en) | Co-crystals of ibrutinib with carboxylic acids | |
| JP2017206516A (ja) | プリドピジン塩酸塩の新規な多形形態 | |
| JP7473486B2 (ja) | Ｒａｄ１９０１－２ｈｃｌの多形形態 | |
| RU2460728C2 (ru) | Соль моносульфат 2-хлор-4-[1-(4-фторфенил)-2,5-диметил-1н-имидазол-4-илэтинил]-пиридина и ее кристаллическая форма, содержащая их фармацевтическая композиция и способ получения | |
| KR20210134837A (ko) | Rad1901-2hcl의 다형 형태 | |
| CN104031049A (zh) | 极光激酶抑制剂的结晶形式 | |
| AU2018378348B2 (en) | Crystal forms and production methods thereof | |
| US8163790B2 (en) | Metronidazole cocrystals and imipramine cocrystals | |
| KR20150002767A (ko) | 결정질 형태의 (S)-4-아미노-N-(1-(4-클로로페닐)-3-히드록시프로필)-1-(7H-피롤로[2,3-ｄ]-피리미딘-4-일)피페리딘-4-카르복사미드 | |
| CZ2016548A3 (cs) | Pevné formy eluxadolinu | |
| JP7152122B2 (ja) | エダラボン塩 | |
| WO2017186197A1 (en) | Salts of lenvatinib | |
| EP3587421A1 (en) | Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide | |
| CZ305096B6 (cs) | Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice | |
| US20190352269A1 (en) | Method for producing a polymorphic form of 3-[5-amino-4-(3- cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide | |
| EP3484853B9 (en) | Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide | |
| Gwachha | Solid State Characterization of 3-(5-methoxy, 2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one (MOMIPP) and its solvates | |
| CZ2014478A3 (cs) | Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice | |
| EP4041736A1 (en) | Amorphous form or crystalline form of 2-indolinolinololylspironone compounds or their salts, solvent complexes | |
| Bobrovs | Solvent mediated phase transformations of active pharmaceutical compounds tegafur and theophylline | |
| EA042657B1 (ru) | Соли соединения и их кристаллические формы | |
| TW201636346A (zh) | 二－匹多莫德苄乙二胺及其固體型 | |
| CZ201497A3 (cs) | Krystalické formy enzalutamidu |